Program
SHR-4375
A development code. Also written as “SHR-4375 Injection”.
In Jiangsu HengRui Medicine's pipeline, TF ADC
. Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Jan 2, 20252 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 22 open or running | phase 2since Jan 2, 2025 | Jan 2, 2025 | Jan 2027phase 2 · NCT07298772 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-4375
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2025First study: phase 2 study in Solid TumorsFirst studyNCT06764628 · 208 planned · China
- Dec 9, 2025Phase 2 study in Advanced Solid TumorNCT07298772 · 198 planned · China
Ahead
- Jan 2027Primary completion: phase 2 study in Advanced Solid TumorNCT07298772
- May 2027Primary completion: phase 2 study in Solid TumorsNCT06764628
TargetBeta
“TF ADC”the company's pipeline, read by Claude · source
Other programs on F3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tisotumab vedotinrule | Pfizer | phase 4 | 11 |
| Anti-TF/TOP1i Antibody-drug Conjugate XNW28012rule | Evopoint Biosciences | phase 3 | 3 |
| Anti-TF Antibody-drug Conjugate MRG004Arule | lepu-biopharma-co-ltd | phase 3 | 2 |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 1 |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | sutro-biopharma-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07298772Advanced Solid Tumor · China | 2 | Recruiting | Jan 2027 | 198 |
| NCT06764628Solid Tumors · China | 2 | Recruiting | May 2027 | 208 |
How it is read
Names in the registry
- “SHR-4375 Injection”, 1 entry
- “SHR-4375”, 1 entry
Codes read as this program: SHR4375.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.